| Objective To explore the clinical characteristics and treatment status of patients with non valvular atrial fibrillation(NVAF)in order to promote its clinical outcome.Methods From June 2017 to June 2019,472 patients with non-valvular atrial fibrillation diagnosed in the cardiology department of XX Medical University General Hospital were selected.The demographic characteristics,combined diseases,types of atrial fibrillation,course of disease,ejection fraction,left anterior posterior diameter,left ventricular diastolic diameter,CHA2DS2-VASc score,anticoagulant therapy,cerebral or systemic embolism events were studied by retrospective method Occurrence of disease.Results Tthere were 472 patients with non-valvular atrial fibrillation,most of them were male,the ratio of male to female was 1.91:1,the age was 31-89 years(average67.29 ± 10.34),the most of them were 65-74 years old,there were 177 cases(37.5%),followed by 50-64 years old(30.1%),75 years old(27.1%)and 50 years old(5.3%);The top four combined diseases are: hypertension(48.9%),coronary heart disease(37.5%),diabetes(20.8%),heart failure(17.6%);289 cases of paroxysmal atrial fibrillation(61.2%),170 cases of persistent atrial fibrillation(36.0%);331 cases(70.1%)with a course of less than 1 year,110 cases(23.3%)with a course of 1 to 5 years(including 5years);64.4% of patients with the increase of left atrium diameter,12.7% with the increase of left ventricular diastolic diameter and 7.63% with the decrease of left ventricular ejection fraction;CHA2DS2-VASc thromboembolism risk scoring system score was 0 score in 56 cases(11.9%),1 score in 89 cases(18.9%),? 2 score in 327 cases(69.3%),most of them were patients with high risk of thromboembolism;anticoagulation treatment rate of middle and high risk patients was 36.54%,warfarin accounted for 51.3%,new oral administration Anticoagulants accounted for 48.7%,and the clinical use rate of new oral anticoagulants increased significantly.Among all the patients in the study,155 were treated with radiofrequency ablation,accounting for32.8%,of which paroxysmal atrial fibrillation accounted for 70.3%,the success rate was83.5%,persistent atrial fibrillation accounted for 29.7%,the success rate was 58.7%,and the success rate of paroxysmal atrial fibrillation was higher than that of persistent atrial fibrillation(P<0.05).The incidence of systemic embolism was 25.6%.There were 113cases(27.2%)with cerebral and systemic circulation embolism in middle and high risk patients.Compared with the three groups,the incidence of embolism in non treatment group was higher than that in warfarin anticoagulation group and new oral drug anticoagulation group(P < 0.05).There was no significant difference between warfarin anticoagulation group and new oral drug anticoagulation group(P > 0.05),68 cases(17.48%)had heart failure during the follow-up.Conclusion 1.NVAF patients are more common in the elderly.Most of them have comorbidities,and have enlarged heart and reduced cardiac function.2.Most are high-risk patients with thromboembolism,and the rate of anticoagulation treatment is even low in such patients.3.Anticoagulation treatment can significantly reduce the incidence of embolism events.The NOAC clinical application is more and more widely.The cases treated with catheter ablation is significantly increased. |
PDF Full Text Request